BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2023-10

216 industry Phase 2/3 trial readout(s) and 44 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2023-09 | 2023-11 →

FDA decision events

DateEventStatusCompanyDrugSource
2023-10-02FDA approvalapprovedVIFOR PHARMAVELTASSAApproved 2023-10-02: VELTASSA (NDA205739 SUPPL38)
2023-10-03FDA approvalapprovedSAMSUNG BIOEPIS CO LTDBYOOVIZApproved 2023-10-03: BYOOVIZ (BLA761202 SUPPL6)
2023-10-03FDA approvalapprovedGENENTECH INCEVRYSDIApproved 2023-10-03: EVRYSDI (NDA213535 SUPPL11)
2023-10-04FDA approvalapprovedPFIZER INC PFEABRILADAApproved 2023-10-04: ABRILADA (BLA761118 SUPPL7)
2023-10-05FDA approvalapprovedARCUTIS ARQTZORYVEApproved 2023-10-05: ZORYVE (NDA215985 SUPPL2)
2023-10-06FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2023-10-06: COSENTYX (BLA761349 ORIG1)
2023-10-11Complete response letterapproved sinceAlvotech USA Inc. ALVOAVT04CRL 2023-10-11: Alvotech USA Inc. BLA 761343 (AVT04)
2023-10-11FDA approvalapprovedARRAY BIOPHARMA INC ADBRAFTOVIApproved 2023-10-11: BRAFTOVI (NDA210496 SUPPL14)
2023-10-11FDA approvalapprovedARRAY BIOPHARMA INC ADMEKTOVIApproved 2023-10-11: MEKTOVI (NDA210498 SUPPL9)
2023-10-12FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2023-10-12: KEYTRUDA (BLA125514 SUPPL138)
2023-10-12FDA approvalapprovedPFIZER PFEVELSIPITYApproved 2023-10-12: VELSIPITY (NDA216956 ORIG1)
2023-10-13FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2023-10-13: OPDIVO (BLA125554 SUPPL121)
2023-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2023-10-16: KEYTRUDA (BLA125514 SUPPL139)
2023-10-17FDA approvalapprovedHIKMACOMBOGESIC IVApproved 2023-10-17: COMBOGESIC IV (NDA215320 ORIG1)
2023-10-17FDA approvalapprovedUCB INCBIMZELXApproved 2023-10-17: BIMZELX (BLA761151 ORIG1)
2023-10-17FDA approvalapprovedORASIS PHARMSQLOSIApproved 2023-10-17: QLOSI (NDA217836 ORIG1)
2023-10-17FDA approvalapprovedUCB INCZILBRYSQApproved 2023-10-17: ZILBRYSQ (NDA216834 ORIG1)
2023-10-17FDA approvalapprovedARDELYX INC ARDXXPHOZAHApproved 2023-10-17: XPHOZAH (NDA213931 ORIG1)
2023-10-18FDA approvalapprovedZYDUS LIFESCIENCESZITUVIOApproved 2023-10-18: ZITUVIO (NDA211566 ORIG1)
2023-10-18FDA approvalapprovedIMMUNEXENBRELApproved 2023-10-18: ENBREL (BLA103795 SUPPL5595)
2023-10-18FDA approvalapprovedDAIICHI SANKYO INCSAVAYSAApproved 2023-10-18: SAVAYSA (NDA206316 SUPPL19)
2023-10-18FDA approvalapprovedDAIICHI SANKYO INCSAVAYSAApproved 2023-10-18: SAVAYSA (NDA206316 SUPPL21)
2023-10-20FDA approvalapprovedBIOMARIN PHARM BMRNVOXZOGOApproved 2023-10-20: VOXZOGO (NDA214938 SUPPL2)
2023-10-20FDA approvalapprovedBAUSCH BLCOCABTREOApproved 2023-10-20: CABTREO (NDA216632 ORIG1)
2023-10-20FDA approvalapprovedSOLUBIOMIXCOXANTOApproved 2023-10-20: COXANTO (NDA217927 ORIG1)
2023-10-20FDA approvalapprovedCELLTRIONZYMFENTRAApproved 2023-10-20: ZYMFENTRA (BLA761358 ORIG1)
2023-10-20FDA approvalapprovedGENENTECH INCROZLYTREKApproved 2023-10-20: ROZLYTREK (NDA212725 SUPPL9)
2023-10-20FDA approvalapprovedJAZZ PHARMS RES JAZZEPIDIOLEXApproved 2023-10-20: EPIDIOLEX (NDA210365 SUPPL20)
2023-10-20FDA approvalapprovedGENENTECH INCROZLYTREKApproved 2023-10-20: ROZLYTREK (NDA218550 ORIG1)
2023-10-23FDA approvalapprovedEISAI INCLENVIMAApproved 2023-10-23: LENVIMA (NDA206947 SUPPL28)
2023-10-23FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2023-10-23: KEYTRUDA (BLA125514 SUPPL142)
2023-10-23FDA approvalapprovedSANOFI AVENTIS US SNYMULTAQApproved 2023-10-23: MULTAQ (NDA022425 SUPPL30)
2023-10-24FDA approvalapprovedSERVIERTIBSOVOApproved 2023-10-24: TIBSOVO (NDA211192 SUPPL11)
2023-10-26FDA approvalapprovedGENENTECH INCVABYSMOApproved 2023-10-26: VABYSMO (BLA761235 SUPPL3)
2023-10-26FDA approvalapprovedELI LILLY AND CO LLYOMVOHApproved 2023-10-26: OMVOH (BLA761279 ORIG1)
2023-10-26FDA approvalapprovedCATALYST PHARMSAGAMREEApproved 2023-10-26: AGAMREE (NDA215239 ORIG1)
2023-10-27FDA approvalapprovedCOHERUS BIOSCIENCES INC CHRSLOQTORZIApproved 2023-10-27: LOQTORZI (BLA761240 ORIG1)
2023-10-30FDA approvalapprovedBRISTOL MYERS SQUIBB BMYORENCIAApproved 2023-10-30: ORENCIA (BLA125118 SUPPL250)
2023-10-31FDA AdComheldVertex Pharmaceuticals, Inc. VERXAdCom 2023-10-31: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125787
2023-10-31FDA approvalapprovedAMGEN INC AMGNWEZLANAApproved 2023-10-31: WEZLANA (BLA761285 ORIG1)
2023-10-31FDA approvalapprovedAMGEN INC AMGNWEZLANAApproved 2023-10-31: WEZLANA (BLA761331 ORIG1)
2023-10-31FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2023-10-31: COSENTYX (BLA125504 SUPPL63)
2023-10-31FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2023-10-31: KEYTRUDA (BLA125514 SUPPL145)
2023-10-31FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2023-10-31: KEYTRUDA (BLA125514 SUPPL144)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2023-10 est.P1/P2Tyme, IncNCT02562612 Study of SM-88 in Advanced CancersBreast Cancerwithdrawn
2023-10 est.P3EMSNCT03766750 Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.Type2 Diabetes Mellituswithdrawn
2023-10 est.P3Shanghai Henlius BiotechNCT04139135 A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerGastric Cancerunknown642
2023-10 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05117658 Study of HA121-28 in Patients With Non-Small Cell Lung CancerNSCLCunknown83
2023-10 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05339802 A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure InfectionsSkin Infectionunknown90
2023-10 est.P3AIM Vaccine Co., Ltd.NCT05428592 Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in IslamabadSARS-CoV-2unknown1100
2023-10 est.P3Chong Kun Dang PharmaceuticalNCT05526703 Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination TherapyEssential Hypertensionunknown108
2023-10 est.P3National Vaccine and Serum Institute, ChinaNCT05599516 Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical TrialCOVID-19; Coronavirus Infectionsunknown16000
2023-10 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT05602129 A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy SubjecRenal Replacement Therapyunknown156
2023-10 est.P3Palvella Therapeutics, Inc. PVLANCT05643872 A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPachyonychia Congenitarecruiting45
2023-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT05823246 Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial CarcinomaMelanoma; Urothelial Carcinomaunknown66
2023-10-01 est.P3Neutec Ar-Ge San ve Tic A.ŞNCT03729258 Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.Sinusitis; Sinusitis, Acute; Rhinosinusitis; Rhinosinusitis Acute; Sinus Infectionunknown100
2023-10-01 est.P3Shanghai Henlius BiotechNCT03952403 A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Carcinoma; Non-Small-Cell Lungunknown643
2023-10-01P3Rain Oncology IncNCT04979442 Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated LiposarcomaDedifferentiated Liposarcomaterminated175
2023-10-01P1/P2ZEO ScientifiX, Inc. ZEOXNCT05228899 Zofin to Treat COVID-19 Long HaulersCOVID-19completed18
2023-10-01 est.P1/P2China National Biotec Group Company LimitedNCT05365724 A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveCOVID-19unknown280
2023-10-01 est.P3Zhejiang Teruisi Pharmaceutical Inc.NCT05378867 A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRCMetastatic Colorectal Cancer (CRC)unknown126
2023-10-01P2Kinarus AGNCT05659459 The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2COVID-19terminated17
2023-10-01P1/P2Suzhou Junjing BioSciences Co., Ltd.NCT05662670 A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung CancerLocally Advanced or Metastatic NSCLCterminated14
2023-10-02P2Novartis Pharmaceuticals NVSNCT01863745 Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib TreatmentGastrointestinal Stromal Tumorscompleted15
2023-10-02P2Pfizer PFENCT02850406 Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseSickle Cell Diseaseterminated147
2023-10-02P3Vertex Pharmaceuticals Incorporated VERXNCT03277196 A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation Cystic Fibrosiscompleted86
2023-10-02P3Merck Sharp & Dohme LLC MRKNCT03884101 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)Endometrial Neoplasmscompleted842
2023-10-02P3GlaxoSmithKlineNCT04246047 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With ReMultiple Myelomaactive not recruiting494
2023-10-02P3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338022 Study of Evobrutinib in Participants With RMS (evolutionRMS 1)Relapsing Multiple Sclerosisterminated1124
2023-10-02P3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338061 Study of Evobrutinib in Participants With RMS (evolutionRMS 2)Relapsing Multiple Sclerosisterminated1166
2023-10-02P3Boston Scientific Corporation BSXNCT04647253 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)In-Stent Restenosisactive not recruiting600
2023-10-02P2AbbVie ABBVNCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular Degeneration; Wet Macular Degeneration; Wet Age-related Macular Degecompleted60
2023-10-02P3Merck Sharp & Dohme LLC MRKNCT04865289 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyEndometrial Neoplasmscompleted130
2023-10-02P2Sagimet Biosciences Inc. SGMTNCT04906421 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Diseasecompleted168
2023-10-02P2NFlection Therapeutics, Inc.NCT05005845 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)Cutaneous Neurofibroma; Neurofibromatosis 1completed199
2023-10-02P3SK Bioscience Co., Ltd.NCT05007951 Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)Covid19completed4036
2023-10-02P3Gedeon Richter Plc.NCT05087030 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal OsteoporosisPostmenopausal Osteoporosiscompleted473
2023-10-02P2Zydus Therapeutics Inc.NCT05211284 Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USNonalcoholic Fatty Liver Diseaseterminated4
2023-10-02P2Incyte Corporation INCYNCT05593432 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen PlanusCutaneous Lichen Planuscompleted64
2023-10-02P3Pfizer PFENCT05875727 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.Pneumococcal Diseasecompleted405
2023-10-03P2Acurx Pharmaceuticals Inc. ACXPNCT04247542 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionClostridium Difficile Infectioncompleted53
2023-10-03P2ITB-Med LLCNCT04311632 A Dose Escalation Study in de Novo Renal TransplantationKidney Transplantationcompleted13
2023-10-03P3Janssen Research & Development, LLCNCT04513912 A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Depressive Disorder, Majorcompleted757
2023-10-03P2Highlight TherapeuticsNCT04570332 BO-112 With Pembrolizumab in Unresectable Malignant MelanomaMelanomacompleted42
2023-10-03P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT04659174 An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)Schizophreniacompleted152
2023-10-03P2Dynavax Technologies CorporationNCT05506969 Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of AgePlague, Pneumonic; Plague; Vaccine-Preventable Diseasescompleted200
2023-10-03P3Sanofi Pasteur, a Sanofi Company SNYNCT05513391 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 YearsInfluenza Immunizationterminated366
2023-10-04P1/P2Kyowa Kirin Pharmaceutical Development LtdNCT04188964 Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of AgeX-linked Hypophosphatemia (XLH)completed16
2023-10-04P2BioCryst Pharmaceuticals BCRXNCT04702568 A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria; PNHterminated19
2023-10-04P3BioNTech SE BNTXNCT04816643 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenSARS-CoV-2 Infection, COVID-19completed11837
2023-10-04 est.P3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04951648 A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced oNon-small Cell Lung Cancerunknown220
2023-10-04P3Sarepta Therapeutics, Inc. SRPTNCT05096221 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DDuchenne Muscular Dystrophycompleted126
2023-10-04P2AstraZeneca AZNNCT05375760 A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and PCoronavirus Disease 2019 (COVID-19)terminated251
2023-10-04P3Croma-Pharma GmbHNCT05386030 Saypha® VOLUME Lidocaine for Midface AugmentationModerate to Severe Midface Volume Deficitcompleted562
2023-10-04P2Sention Therapeutics, LLCNCT05412979 A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary HypothyroidismHypothyroidismcompleted490
2023-10-05P3Hoffmann-La RocheNCT02118584 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III StudiesUlcerative Colitisterminated1822
2023-10-05P2Pfizer PFENCT03845517 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)Systemic Lupus Erythematosuscompleted350
2023-10-05P2Hoffmann-La RocheNCT04075266 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisMultiple Sclerosisactive not recruiting23
2023-10-05P1/P2Bristol-Myers Squibb BMYNCT04446650 A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Primary Myelofibrosiscompleted31
2023-10-05P2Hoffmann-La RocheNCT05401565 Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)Stress Disorders, Post-Traumaticcompleted29
2023-10-05P2/P3Cessatech A/SNCT05508594 Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001Paincompleted220
2023-10-06P2Novo Nordisk A/S NVONCT04204408 A Research Study Investigating Mim8 in People With Haemophilia AHealthy Volunteers; Haemophilia A With or Without Inhibitorscompleted275
2023-10-06P2Harmony Biosciences Management, Inc. HRMYNCT04886518 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1Myotonic Dystrophy 1; Excessive Daytime Sleepinesscompleted30
2023-10-06P1/P2Paean Biotechnology Inc.NCT04976140 Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or DermatomyositisPolymyositis; Dermatomyositiscompleted9
2023-10-06P3Bio-Thera SolutionsNCT05046431 Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic ArthritisPsoriatic Arthritiscompleted704
2023-10-06P2Pfizer PFENCT05061446 Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative Colitiscompleted54
2023-10-06P1/P2LaNova Medicines LimitedNCT05255484 Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursAdvanced Solid Tumorterminated24
2023-10-06P2Definium Therapeutics US, Inc. DFTXNCT05407064 A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsAnxiety Generalizedcompleted198
2023-10-06P3AbbVie ABBVNCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult ParticipantsDry Eye Syndromecompleted40
2023-10-06P3Ocumension Therapeutics (Suzhou) Co., LtdNCT06697522 Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in ChildrenMyopiacompleted148
2023-10-08P3Boehringer IngelheimNCT04915729 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical ActivityStrokecompleted1489
2023-10-08P2Tonix Pharmaceuticals, Inc. TNXPNCT05679908 A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineChronic Migraine; Chronic Migraine, Headache; Chronic Migraine Without Aura; Aura Migrainecompleted88
2023-10-08P2/P3Jiaxing AnDiCon Biotech Co.,LtdNCT06342921 ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus InfectionSafety Issues; Effect of Drugcompleted749
2023-10-09P3Hoffmann-La RocheNCT02403323 Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144Crohn Diseaseterminated790
2023-10-09P1/P2Laekna LimitedNCT03843918 A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate CancerProstate Cancer Metastaticterminated33
2023-10-09P3argenx ARGXNCT04687072 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopeniacompleted207
2023-10-09P2EsoCap AGNCT04849390 A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic EsophagitisEosinophilic Esophagitiscompleted43
2023-10-09P3Inmunotek S.L.NCT04874714 Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisAllergic Rhinoconjunctivitis; Perennial Allergic Rhinitis; House Dust Mite Allergy; Pollen Allergyterminated18
2023-10-09P3Lakefront Biotherapeutics NV LKFTNCT05479058 A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionUlcerative Colitisterminated22
2023-10-10P3GlaxoSmithKlineNCT04010539 A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital GonorrheaGonorrheacompleted628
2023-10-10P3EMSNCT04185441 Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic HyperplasiaErectile Dysfunction; Benign Prostatic Hyperplasiacompleted295
2023-10-10P2AstraZeneca AZNNCT04277546 Open-label Extension Study of Brazikumab in Ulcerative ColitisUlcerative Colitisterminated57
2023-10-10P2Arrevus Inc.NCT05105035 Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized PatientsMelioidosiscompleted125
2023-10-10P2Janssen Research & Development, LLCNCT05653427 A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaCarcinoma, Hepatocellularterminated18
2023-10-10P1/P2Hangzhou Sciwind Biosciences Co., Ltd.NCT05779995 A Study To Evaluate the Safety of XW001 Inhalation in Children With RSVRSV Infectioncompleted61
2023-10-11P2Merck Sharp & Dohme LLC MRKNCT03776136 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/Advanced Melanomacompleted103
2023-10-11P3Hoffmann-La RocheNCT04432831 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular EdemaDiabetic Macular Edemacompleted1479
2023-10-11P3Novo Nordisk A/S NVONCT04916470 Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesHeart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2completed617
2023-10-11P1/P2Allogene Therapeutics ALLONCT05000450 Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myelomaterminated6
2023-10-11P2Merck Sharp & Dohme LLC MRKNCT05008224 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)Classical Hodgkin Lymphomacompleted146
2023-10-11P1/P2Pfizer PFENCT05261490 Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerOvarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancterminated10
2023-10-11P3Sylentis, S.A.NCT05310422 Safety Study of Tivanisiran to Treat Dry EyeDry Eye Diseasecompleted301
2023-10-11P3Opus Genetics, Inc IRDNCT05646719 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPresbyopiacompleted333
2023-10-12P1/P2Hoffmann-La RocheNCT03677141 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-PolatuzuB-cell Non-Hodgkin Lymphomacompleted117
2023-10-12P2Kite, A Gilead CompanyNCT03761056 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaB-cell Lymphomacompleted42
2023-10-12P1/P2Dizal PharmaceuticalsNCT04105010 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)Relapsed or Refractory Peripheral T Cell Lymphomacompleted171
2023-10-12P2Novartis Pharmaceuticals NVSNCT04677595 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNon-Small Cell Lung Cancer (NSCLC)completed36
2023-10-12P2/P3Sumitomo Pharma Co., Ltd.NCT04825860 A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension PhaseSchizophreniaterminated83
2023-10-12P2Boehringer IngelheimNCT05103657 A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress DisorderPost-Traumatic Stress Disordercompleted318
2023-10-12P3Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.NCT05151328 Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional ConstipationFunctional Constipationcompleted648
2023-10-12P2Novo Nordisk A/S NVONCT05486065 A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and OverweightDiabetes Mellitus, Type 2completed245
2023-10-12P2Vertex Pharmaceuticals Incorporated VERXNCT05660538 Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)Diabetic Peripheral Neuropathycompleted194
2023-10-13P2/P3Geron Corporation GERNNCT02598661 Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (Myelodysplastic Syndromesactive not recruiting289
2023-10-13P1/P2ViaCyteNCT03163511 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia UnawarenessType 1 Diabetes Mellitus With Hypoglycemiacompleted49
2023-10-13P1/P2Incyte Corporation INCYNCT03978637 Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationBronchiolitis Obliterans Syndrometerminated23
2023-10-13P3Lee's Pharmaceutical LimitedNCT04878016 A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLCExtensive-stage Small-cell Lung Cancercompleted498
2023-10-13 est.P3Shandong New Time Pharmaceutical Co., LTDNCT05040906 A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsRecruitingunknown416
2023-10-13P2Azura OphthalmicsNCT05548491 Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)Contact Lens Discomfortcompleted67
2023-10-13P3Braintree LaboratoriesNCT05587322 A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux DiseaseNon-erosive Reflux Diseasecompleted788
2023-10-15 est.P2/P3Bausch Health Americas, Inc.NCT04083651 A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerPancreatic Cancerwithdrawn
2023-10-15 est.P3Shanghai Henlius BiotechNCT04465734 A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally AdvHepatocellular Carcinoma (HCC)withdrawn
2023-10-15P2Rain Oncology IncNCT05012397 Milademetan in Advanced/Metastatic Solid TumorsSolid Tumors; Head and Neck Carcinoma; Cholangiocarcinoma; Sarcoma; Lung Adenocarcinoma; Bladder Uroterminated40
2023-10-15P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05020652 A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisModerate and High Risk Myelofibrosiscompleted107
2023-10-16P2Cardiff Oncology CRDFNCT03414034 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancercompleted72
2023-10-16P2Entero TherapeuticsNCT04243551 Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD PatientsCeliac Diseaseterminated83
2023-10-16P3Novo Nordisk A/S NVONCT04998136 Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesitycompleted150
2023-10-16P1/P2Cybin IRL LimitedNCT05385783 A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive DisorderMajor Depressive Disordercompleted57
2023-10-16P2Vaxart VXRTNCT05626803 A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersNorovirus Infectionscompleted135
2023-10-16P3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06715319 Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary CirrhosisPBCcompleted100
2023-10-17P3BeiGeneNCT04866017 A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable NonNon Small Cell Lung Cancerterminated63
2023-10-17P3Incyte Corporation INCYNCT05073458 Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaWarm Autoimmune Hemolytic Anemia (wAIHA)terminated13
2023-10-17P2Medipost Co Ltd.NCT05182034 Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee OsteoarthritisKnee Osteoarthritiscompleted94
2023-10-17P3Aerie PharmaceuticalsNCT05360966 Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)Dry Eye Diseasecompleted467
2023-10-18P2Regeneron Pharmaceuticals REGNNCT02760498 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell CarcinomaAdvanced Cutaneous Squamous Cell Carcinomacompleted432
2023-10-18P2/P3AstraZeneca AZNNCT03759288 An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's DiseaseCrohn's Disease; IBDterminated89
2023-10-18P1/P2Kolon Life ScienceNCT04238793 Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral RadiculopathyNeuropathic Pain From Lumbosacral Radiculopathycompleted18
2023-10-18P3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04617028 Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisMyelofibrosiscompleted105
2023-10-18P2Achilles Therapeutics UK LimitedNCT04785365 Long-Term Follow-Up Study of Patients Receiving ATL001Melanoma; Advanced Non Small Cell Lung Cancerterminated1
2023-10-18P1/P2PureTech PTCHFNCT05129865 LYT-300 in Healthy VolunteersHealthy Volunteerscompleted186
2023-10-18P3Sumitomo Pharma America, Inc.NCT05169710 A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.Depressive Episodes, Bipolar I Depressionterminated83
2023-10-18P2Neurocrine UK Limited NBIXNCT05222152 Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal InsufficiencyPrimary Adrenal Insufficiencycompleted58
2023-10-18P2Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT05291689 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCInflammatory Bowel Diseases; Colitis, Ulcerativecompleted39
2023-10-19P1/P2Autolus Limited AUTLNCT03287817 Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)terminated52
2023-10-19P2Pfizer PFENCT03395184 Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCrohn's Diseasecompleted244
2023-10-19P2OncotherapeuticsNCT03733691 Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsNewly Diagnosed Multiple Myelomaterminated19
2023-10-19P3NS Pharma, Inc.NCT04060199 Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)Duchenne Muscular Dystrophycompleted77
2023-10-19P2Janssen Research & Development, LLCNCT04535544 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D VirusHepatitis D, Chroniccompleted52
2023-10-19P2Pulmocide LtdNCT05037851 An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S StuPulmonary Aspergillosiscompleted102
2023-10-19P3Veru Inc. VERUNCT05065411 Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerMetastatic Breast Cancerterminated5
2023-10-19P3Rhythm Pharmaceuticals, Inc. RYTMNCT05194124 Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiencycompleted19
2023-10-19P2/P3Jiangsu HengRui Medicine Co., Ltd.NCT05375305 A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic SurgeryPaincompleted320
2023-10-19P2Incyte Corporation INCYNCT05635838 Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaHidradenitis Suppurativacompleted69
2023-10-19P2Merz Aesthetics GmbHNCT05773053 A Study of NT 201 Doses in the Treatment of Platysma ProminencePlatysma Prominencecompleted73
2023-10-19P2Longbio PharmaNCT06046391 Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis AdultSeasonal Allergic Rhinitiscompleted180
2023-10-20P2/P3Janssen Research & Development, LLCNCT03466411 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCrohn's Diseaseactive not recruiting1409
2023-10-20P3Sanofi Pasteur, a Sanofi Company SNYNCT03691610 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants Healthy Volunteers (Meningococcal Infection)completed950
2023-10-20P3Gilead Sciences GILDNCT03901339 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerMetastatic Breast Cancercompleted543
2023-10-20P2HemoShear TherapeuticsNCT04732429 Study of HST5040 in Subjects With Propionic or Methylmalonic AcidemiaMethylmalonic Acidemia; Propionic Acidemiaterminated26
2023-10-20P2BeiGeneNCT05014828 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsAdvanced Solid Tumorcompleted58
2023-10-20P2LEO PharmaNCT05388760 Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)Atopic Dermatitiscompleted28
2023-10-20P3Sanofi SNYNCT05413369 iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)Type 2 Diabetes Mellituscompleted582
2023-10-20P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT05536726 A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque PsoriasisPsoriasiscompleted458
2023-10-20P2Noema Pharma AGNCT05583955 A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)Childhood-Onset Fluency Disordercompleted75
2023-10-20P2/P3Taisho Pharmaceutical IndonesiaNCT07482046 Effectiveness of Topical Menthol as A Cooling Method During Exercise in A Recreational Runner PopulationHeat Stress; Athletic Performancecompleted37
2023-10-22P1/P2Gan and Lee Pharmaceuticals, USANCT06256536 A Study of GZR18 Injection in Chinese Obese/Overweight PatientsObesity; Overweightcompleted60
2023-10-23P3CelgeneNCT03575351 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory AggressivLymphoma, Non-Hodgkincompleted184
2023-10-23P2AstraZeneca AZNNCT03616821 Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitis; IBDterminated242
2023-10-23P2Anterogen Co., Ltd.NCT03754465 Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot UlcersDiabetic Foot Ulcercompleted66
2023-10-23P2Janssen Research & Development, LLCNCT04523207 A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastaProstatic Neoplasmscompleted108
2023-10-23P1/P2Amgen AMGNNCT04631601 Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate Cancerterminated55
2023-10-23P2Janssen Research & Development, LLCNCT04968912 A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)Sjogren's Syndromecompleted163
2023-10-23P2Eli Lilly and Company LLYNCT05565742 A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]Lipoprotein Disordercompleted320
2023-10-23P2Xiamen Amoytop Biotech Co., Ltd.NCT05838885 A Trial of YPEG-rhGH in Children With Short StatureIdiopathic Short Stature; Small for Gestational Age; Turner Syndromecompleted78
2023-10-25 est.P1/P2Haihe Biopharma Co., Ltd.NCT04270591 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerC-Met Exon 14 Mutationrecruiting183
2023-10-25P2Shanghai Ming Ju Biotechnology Co., Ltd.NCT04718883 CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaMantle Cell Lymphomaactive not recruiting59
2023-10-25P3Takeda TAKNCT05543174 A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)Alagille Syndrome (ALGS)completed7
2023-10-25P3Innovent Biologics (Suzhou) Co. Ltd.NCT05628311 A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseType 2 Diabetescompleted319
2023-10-26P2/P3SyneuRx International (Taiwan) CorpNCT01908192 Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®Schizophreniaterminated60
2023-10-26P3Pfizer PFENCT02791230 Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyTransthyretin (TTR) Amyloid Cardiomyopathycompleted1733
2023-10-26P1/P2Eisai Inc.NCT03250676 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerBreast Neoplasms; Breast Cancer; Estrogen-receptor Positive Breast Cancer; Cancer, Breast; Breast Cacompleted151
2023-10-26 est.P2Pfizer PFENCT04209556 A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisUlcerative Colitiswithdrawn
2023-10-26P3AstraZeneca AZNNCT04612790 A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.Bullous Pemphigoidterminated67
2023-10-26P1/P2AkesoNCT04646330 A Trial of AK104 Plus Anlotinib in NSCLCNSCLCcompleted114
2023-10-26P1/P2XBiotech, Inc. XBITNCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerPancreatic Cancercompleted76
2023-10-26P2Novartis Pharmaceuticals NVSNCT04878432 STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDSMyelodysplastic Syndrome (MDS)terminated39
2023-10-26P2/P3Alexion Pharmaceuticals, Inc.NCT04999020 Ravulizumab Versus Placebo in Adult Participants With DermatomyositisDermatomyositisterminated38
2023-10-26P3Ferrer Internacional S.A.NCT05178810 Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosiscompleted313
2023-10-26 est.P2Inmune Bio, Inc. INMBNCT05321498 Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationMild Cognitive Impairment (MCI); Alzheimer Disease; Dementia; Brain Diseases; Central Nervous Systemwithdrawn
2023-10-26P2Aclaris Therapeutics, Inc. ACRSNCT05432596 Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisAtopic Dermatitiscompleted250
2023-10-26P1/P2Novartis Pharmaceuticals NVSNCT05447663 A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell TransplantAcute Myeloid Leukemia; Allogeneic Stem Cell Transplantationterminated8
2023-10-26P1/P2Shanghai Pharmaceuticals Holding Co., LtdNCT05905614 Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid TumorsAdvanced Solid Tumorscompleted29
2023-10-26P3Sinovac Life Sciences Co., Ltd.NCT06049940 Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old PopulationTetanuscompleted1260
2023-10-27P2AstraZeneca AZNNCT00378482 A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially AColorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms; Patients Who Hcompleted37
2023-10-27P1/P2OBI Pharma, IncNCT04084366 Phase 1/2 Study of OBI-999 in Patients With Advanced Solid TumorsLocally Advanced Solid Tumorterminated44
2023-10-27P3Pfizer PFENCT04424316 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.Respiratory Tract Infectioncompleted14727
2023-10-27P2Novartis Pharmaceuticals NVSNCT05111249 A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's DiseaseEarly Manifest Huntington Diseaseterminated26
2023-10-27P3Sanofi Pasteur, a Sanofi Company SNYNCT05513053 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.Influenza Immunizationcompleted1308
2023-10-27P3Acrotech Biopharma Inc.NCT05608343 This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)Atopic Dermatitiscompleted153
2023-10-30P2PTC Therapeutics PTCNCT02352896 Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromeLeigh Syndromecompleted30
2023-10-30P3Merck Sharp & Dohme LLC MRKNCT03493542 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young WPrevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN)completed766
2023-10-30P2Sarepta Therapeutics, Inc. SRPTNCT04004065 Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy AmenaDuchenne Muscular Dystrophyterminated62
2023-10-30P3Novartis Pharmaceuticals NVSNCT04278417 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic RetinopathyProliferative Diabetic Retinopathycompleted689
2023-10-30P3Novartis Pharmaceuticals NVSNCT04659863 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial HypercholesterolemiaFamilial Hypercholesterolemia - Homozygouscompleted13
2023-10-30P1/P2Mereo BioPharma MREONCT04761198 A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsSolid Tumor, Adult; Advanced Solid Tumor; Metastatic Solid Tumorcompleted76
2023-10-30P2Oryzon Genomics S.A.NCT04932291 Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder PopulationBorderline Personality Disordercompleted211
2023-10-30 est.P2Halucenex Life Sciences Inc.NCT05243329 Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderTreatment Resistant Disorders; Post Traumatic Stress Disorderunknown20
2023-10-30 est.P1/P2E2Bio Life Sciences, LLCNCT05338398 Study for the Prevention of Oral Mucositis (SPOM)Oral Mucositisunknown100
2023-10-30 est.P1/P2Keymed Biosciences Co.LtdNCT05465707 A Study of CM313 Injection in Subjects With Systemic Lupus ErythematosusSystemic Lupus Erythematosusunknown40
2023-10-30P3Merck Sharp & Dohme LLC MRKNCT05569954 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)Pneumococcal Diseasecompleted1484
2023-10-30P3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05769855 A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing HemorrhoidectomyPostsurgical Pain Managementcompleted294
2023-10-30P2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06113731 A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 VaccineSARS-CoV-2 Infectionunknown980
2023-10-31P1/P2Prescient Therapeutics, Ltd.NCT02930109 A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute LeukemiaAcute Leukemiacompleted33
2023-10-31P3AB2 Bio Ltd.NCT03113760 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP DeficiencyNLRC4-MAS; XIAP Deficiencycompleted15
2023-10-31 est.P1/P2Immix Biopharma Australia Pty Ltd IMMXNCT03382340 IMX-110 in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumors; Pancreatic Cancer; Breast Cancer; Ovarian Cancerunknown70
2023-10-31P1/P2BioXcel Therapeutics Inc BTAIQNCT03910660 A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine PrProstate Cancer; Neuroendocrine Tumors; Small Cell Carcinomacompleted97
2023-10-31P3Bristol-Myers Squibb BMYNCT04149574 A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-MuUrinary Bladder Neoplasmsterminated13
2023-10-31P2Laekna LimitedNCT04374630 Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianPlatinum-resistant Ovarian Cancercompleted150
2023-10-31 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04385550 A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaAdvanced Gastric and Gastro-oesophageal Junction Adenocarcinomaunknown528
2023-10-31 est.P2SafelyYouNCT04478149 A Comprehensive Fall Prevention System for Memory Care: Final Feasibility and Randomized Controlled StudyDementiaunknown300
2023-10-31P2Resolve TherapeuticsNCT04944121 Phase 2 Study of RSLV-132 in Subjects With Long COVIDPost-acute Corona Virus 19 (COVID-19) (Long COVID)completed112
2023-10-31 est.P2Guizhou Bailing Group Pharmaceutical Co LtdNCT05007262 Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic RetinopathyType2 Diabetes; Diabetic Retinopathyunknown240
2023-10-31 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05027204 A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Squamous Cell Carcinoma of Head and Neckunknown94
2023-10-31P1/P2Advagene Biopharma Co. Ltd.NCT05069610 Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19COVID-19completed30
2023-10-31P3Keymed Biosciences Co.LtdNCT05265923 A Study of CM310 in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitiscompleted500
2023-10-31 est.P3Jeil Pharmaceutical Co., Ltd.NCT05296044 To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinType 2 Diabetes Mellitusunknown245
2023-10-31P2Amgen AMGNNCT05430854 Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudySystemic Lupus Erythematosusterminated155
2023-10-31 est.P3Reistone Biopharma Company LimitedNCT05470413 Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia AreataAlopecia Areataunknown330
2023-10-31 est.P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05663411 A Study of SHR6508 in Secondary HyperparathyroidismSecondary Hyperparathyroidismunknown75
2023-10-31P1/P2Valerio TherapeuticsNCT05700669 Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid TumorsMetastatic Castration-resistant Prostate Cancer; Recurrent Epithelial Ovarian Cancer; Breast Cancercompleted3
2023-10-31 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT05961007 Evaluation of IBI302 Injection in nAMD or DMENeovascular Age-related Macular Degeneration; Diabetic Macular Edemasuspended234

← 2023-09 | 2023-11 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.